Search

Displaying results 3171 - 3180 of 7059 in total
  1. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index
  2. Drug

    Triflupromazine

    go.drugbank.com/drugs/DB00508
    ApprovedVet approved

    A phenothiazine used as an antipsychotic agent and as an antiemetic.

    Categories: Dopamine D2 Receptor Antagonists
  3. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

  4. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    FDA approved on July 31, 2009.

  5. Drug

    Calcium glubionate anhydrous

    go.drugbank.com/drugs/DB13142
    Approved

    Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.

    Synonyms: (D-gluconato)(lactobionato)calcium, Calcium D-gluconate lactobionate
  6. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]

  7. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    [A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623] … [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

    Products: LETROZOL 1A PHARMA 2.5MG, LETROZOLO DOC GENERICI
  8. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    [L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events.

  9. Drug

    Urokinase

    go.drugbank.com/drugs/DB00013
    ApprovedInvestigationalWithdrawn

    [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]

  10. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation

    Categories: OCT2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index